Biodexa Pharmaceuticals (BDRX) received Fast Track status from the U.S. Food and Drug Administration for eRapa, a proprietary encapsulated form ...
CARDIFF, UK / ACCESS Newswire / February 12, 2025 /Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage ...
CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatmen ...
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a ...
The U.K. biopharmaceutical company said data from a Phase 2 study of eRapa, a treatment for familial adenomatous polyposis, showed the drug to be safe and well-tolerated among users. The treatment ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Shares of Biodexa Pharmaceuticals skyrocketed nearly 50% on Monday, hitting their highest level since early December. The ...
European equities traded in the US as American depositary receipts were treading water late Wednesday morning, edging 0.03% lower to 1,397.50 on the S&P Europe Select ADR Index. From continental ...